<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02660333</url>
  </required_header>
  <id_info>
    <org_study_id>UFSC</org_study_id>
    <nct_id>NCT02660333</nct_id>
  </id_info>
  <brief_title>Effect of Prebiotic or Synbiotic on Inflammatory Response and Indicators of Nutritional Status in Obesity</brief_title>
  <official_title>Effect of Prebiotic or Synbiotic Supplementation on Inflammatory Response and Indicators of Nutritional Status in Individuals With Morbid Obesity: A Randomized Clinical Trial, Placebo-controlled and Triple Blind</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universidade Federal de Santa Catarina</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universidade Federal de Santa Catarina</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effect of prebiotic or synbiotic supplementation
      on inflammatory response and indicators of nutritional status in patients with morbid
      obesity. Study hypothesis: Supplementation of 12 g/day of fructooligosaccharides (prebiotic)
      or 12 g/day of fructooligosaccharides + strains of lactobacilli and bifidobacteria
      (synbiotic) during 30 days promotes reduction of plasma/serum levels of acute phase proteins,
      cytokines, metabolic and anthropometric parameters in individuals with BMI ≥ 40kg/m².
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to evaluate the effect of prebiotic or synbiotic supplementation
      on inflammatory response and indicators of nutritional status in patients with morbid
      obesity. Adult individuals of both sexes with morbid obesity (body mass index ≥ 40 kg/m²)
      will be invited to participate in this randomized, placebo-controlled, triple-blind study.
      The participants will be divided into three groups: G1 - control group (placebo), G2 -
      prebiotic group and G3 - synbiotic group. The study will consist of four experimental time
      points: M0 - baseline and start of supplementation; M1 - after fifteen days of the first
      outpatient visit and fifteen days after the start of supplementation with prebiotic,
      synbiotic or placebo; M2 - after thirty days from the first outpatient visit and end of
      supplementation with prebiotic, synbiotic and placebo; and M3 - time after sixty days from
      the first outpatient visit. At all time points the inflammatory response will be assessed by
      determination of plasma cytokines (IL-1, IL-6, IL-10, TNF) and acute phase proteins
      (c-reactive protein and albumin), besides the evaluation of laboratory and anthropometric
      indicators of nutritional status. The primary endpoint will be the reduction in
      concentrations of inflammatory markers (cytokines and acute phase proteins).

      Investigators expect to contribute with new information in this field of knowledge, which may
      facilitate the clinical application of these results.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 2016</start_date>
  <completion_date type="Anticipated">July 2018</completion_date>
  <primary_completion_date type="Actual">February 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Study participants and researchers were masked over consumption and distribution of supplementation, respectively. Laboratory technicians who performed the blood collection were also masked as to the distribution of supplementation. Supplements and placebo were pre-packaged by the supplier in opaque and closed sachets with randomization codes, being identical in physical appearance, taste and color. Supplement identification codes were only disclosed by the supplier after statistical analysis of study data.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>C-reactive protein</measure>
    <time_frame>2 months</time_frame>
    <description>Serum C-reactive protein concentrations (mg/L)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cytokines</measure>
    <time_frame>2 months</time_frame>
    <description>Plasma IL-1, IL-6, IL-8, IL-10, IL-12p70 and TNF-alpha concentrations (pg/mL)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Triglycerides</measure>
    <time_frame>2 months</time_frame>
    <description>Serum concentrations of triglycerides (mg/dL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total cholesterol</measure>
    <time_frame>2 months</time_frame>
    <description>Serum concentrations of total cholesterol (mg/dL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LDL-c</measure>
    <time_frame>2 months</time_frame>
    <description>Serum concentrations of LDL-cholesterol (mg/dL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HDL-c</measure>
    <time_frame>2 months</time_frame>
    <description>Serum concentrations of HDL-cholesterol (mg/dL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood glucose</measure>
    <time_frame>2 months</time_frame>
    <description>Blood glucose concentrations (mg/dL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glycated hemoglobin</measure>
    <time_frame>2 months</time_frame>
    <description>Blood concentrations of glycated hemoglobin (%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Growth hormone</measure>
    <time_frame>2 months</time_frame>
    <description>Serum concentrations of Growth hormone (ng/mL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting insulin</measure>
    <time_frame>2 months</time_frame>
    <description>Serum concentrations of insulin (IU/mL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Calcium</measure>
    <time_frame>2 months</time_frame>
    <description>Serum concentrations of calcium (mg/dL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Iron</measure>
    <time_frame>2 months</time_frame>
    <description>Serum concentrations of iron (mg/dL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sodium</measure>
    <time_frame>2 months</time_frame>
    <description>Serum concentrations of sodium (mEq/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Potassium</measure>
    <time_frame>2 months</time_frame>
    <description>Serum concentrations of potassium (mEq/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phosphorus</measure>
    <time_frame>2 months</time_frame>
    <description>Serum concentrations of phosphorus(mg/dL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Folic acid</measure>
    <time_frame>2 months</time_frame>
    <description>Serum concentrations of folic acid (ng/mL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vitamin B12</measure>
    <time_frame>2 months</time_frame>
    <description>Serum concentrations of vitamin B12 (pg/mL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vitamin D</measure>
    <time_frame>2 months</time_frame>
    <description>Serum concentrations of vitamin D (ng/dL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body weight</measure>
    <time_frame>2 months</time_frame>
    <description>Body weight (kg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Waist circumference</measure>
    <time_frame>2 months</time_frame>
    <description>Waist circumference (cm)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body mass index</measure>
    <time_frame>2 months</time_frame>
    <description>Body mass index (kg/m²)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brain-derived neurotrophic factor (BDNF)</measure>
    <time_frame>2 months</time_frame>
    <description>Plasma Brain-derived neurotrophic factor (ng or pg/mL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cortisol</measure>
    <time_frame>2 months</time_frame>
    <description>Plasma cortisol (ug/dL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Leptin</measure>
    <time_frame>2 months</time_frame>
    <description>Plasma leptin (ng/mL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ghrelin</measure>
    <time_frame>2 months</time_frame>
    <description>Plasma ghrelin (pg/mL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adrenocorticotropic Hormone (ACTH)</measure>
    <time_frame>2 months</time_frame>
    <description>Plasma Adrenocorticotropic Hormone (pg/mL)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Morbid Obesity</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Maltodextrin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prebiotic</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fructooligosaccharide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Synbiotic</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fructooligosaccharide + Lactobacillus paracasei LPC-37 + Lactobacillus rhamnosus HN001 + Lactobacillus acidophilus NCFM + Bifidobacterium lactis HN019</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Maltodextrin - 11g/day</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Prebiotic</intervention_name>
    <description>Fructooligosaccharide - 11g/day</description>
    <arm_group_label>Prebiotic</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Synbiotic</intervention_name>
    <description>Fructooligosaccharide + Lactobacillus paracasei LPC-37 + Lactobacillus rhamnosus HN001 + Lactobacillus acidophilus NCFM + Bifidobacterium lactis HN019 - 11g/day</description>
    <arm_group_label>Synbiotic</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age greater than 18 years and less than 60 years

          -  Body mass index (BMI)≥40kg/m2

        Exclusion Criteria:

          -  Previous gastrointestinal diseases (e.g. cancer and inflammatory bowel disease)

          -  Intolerances and/or food allergies (e.g. lactose intolerance and celiac disease)

          -  Current use of anti-inflammatory drugs and/or antibiotics and/or immunosuppressants

          -  Regular use of laxatives and/or appetite suppressants

          -  Current or previous use (up to one month) of prebiotics, probiotics, synbiotics or
             products enriched with these food compounds

          -  Intolerance to prebiotic and/or probiotic and/or synbiotic

          -  Following a diet for weight loss in the last three months

          -  Pregnant or breastfeeding

          -  Following unusual diets (e.g. vegetarian, macrobiotic)

          -  Alcohol dependence and/or illicit drugs dependence

          -  Smokers
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Erasmo Trindade, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Federal University of Santa Catarina</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Polydoro Ernani de São Thiago University Hospital</name>
      <address>
        <city>Florianópolis</city>
        <state>SC</state>
        <zip>88040900</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 14, 2016</study_first_submitted>
  <study_first_submitted_qc>January 18, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 21, 2016</study_first_posted>
  <last_update_submitted>May 21, 2018</last_update_submitted>
  <last_update_submitted_qc>May 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universidade Federal de Santa Catarina</investigator_affiliation>
    <investigator_full_name>Erasmo Benicio Santos de Moraes Trindade</investigator_full_name>
    <investigator_title>Doctor</investigator_title>
  </responsible_party>
  <keyword>Obesity</keyword>
  <keyword>Inflammation</keyword>
  <keyword>Nutritional status</keyword>
  <keyword>Prebiotic</keyword>
  <keyword>Synbiotic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Obesity, Morbid</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

